Servier takes option on Xention's AFib candidate
This article was originally published in Scrip
Executive Summary
Xention, a UK biotech focused on the discovery and development of ion channel-modulating drugs for atrial fibrillation (AF), and French pharma company Servier are to collaborate on the development and commercialization of Xention's only clinical-stage drug candidate XEN-D0103, a selective blocker of Kv1.5, a potassium channel expressed in the atria.